DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 46,530,017 shares of the medical device company's stock after selling 904,784 shares during the quarter. Vanguard Group Inc. owned 11.91% of DexCom worth $3,618,639,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of DXCM. Versant Capital Management Inc purchased a new position in DexCom during the 4th quarter valued at $25,000. Private Trust Co. NA grew its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC increased its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC lifted its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in DexCom in the 4th quarter valued at about $38,000. Institutional investors own 97.75% of the company's stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of research reports. Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and upped their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Finally, Citigroup upped their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus price target of $99.82.

Remove Ads

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 in the last three months. Corporate insiders own 0.30% of the company's stock.

DexCom Stock Down 2.5 %

Shares of DXCM traded down $1.73 during midday trading on Friday, hitting $67.74. 4,680,803 shares of the company's stock traded hands, compared to its average volume of 4,055,857. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $26.47 billion, a price-to-earnings ratio of 47.37, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $141.99. The firm's fifty day moving average is $82.32 and its 200-day moving average is $77.01.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.